Patents by Inventor Lee D. Arnold

Lee D. Arnold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20220162194
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 26, 2022
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11312704
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: April 26, 2022
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20220023311
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 27, 2022
    Inventors: William W. Turner, Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20210380577
    Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: January 14, 2021
    Publication date: December 9, 2021
    Inventors: Leping Li, Lee D. Arnold, Sreenivasa Reddy
  • INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
    Publication number: 20210355111
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 18, 2021
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11174231
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: November 16, 2021
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11124497
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: September 21, 2021
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Cyclic sulfamide compounds and methods of using same
    Patent number: 11078170
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 3, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • Process for making Hepatitis B core protein modulators
    Patent number: 11040965
    Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 22, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: Leping Li, Lee D. Arnold, Sreenivasa Reddy Mundla
  • Process for making Hepatitis B core protein modulators
    Patent number: 11008315
    Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: May 18, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: Leping Li, Lee D. Arnold, Sreenivasa Reddy Mundla
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20210130340
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: May 6, 2021
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • Hepatitis B core protein modulators
    Patent number: 10987360
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B core protein modulators
    Patent number: 10968211
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 6, 2021
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Inhibitors of cyclin-dependent kinases
    Patent number: 10894788
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 19, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME
    Publication number: 20200157070
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: March 1, 2018
    Publication date: May 21, 2020
    Inventors: William W. Turner, JR., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20200131168
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 30, 2020
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20200024266
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 23, 2020
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20200002325
    Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: March 13, 2018
    Publication date: January 2, 2020
    Inventors: Leping Li, Lee D. Arnold, Sreenivasa Reddy
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20190255067
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 22, 2019
    Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Fused bicyclic mTOR inhibitors
    Patent number: 8796455
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 5, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Xin Chen, Heather Coate, Andrew Philip Crew, Han-Qing Dong, Ayako Honda, Mark Joseph Mulvihill, Paula A. R. Tavares, Jing Wang, Douglas S. Werner, Kristen Michelle Mulvihill, Kam W. Siu, Bijoy Panicker, Lee D. Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James David Beard